{"id":"https://openalex.org/W2589564541","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.2548","title":"Pretargeted radioimmunotherapy significantly improves the treatment of non-Hodgkin\u2019s lymphoma in a nude mouse model","display_name":"Pretargeted radioimmunotherapy significantly improves the treatment of non-Hodgkin\u2019s lymphoma in a nude mouse model","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2589564541","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.2548","mag":"2589564541"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.2548","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.2548","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.2548","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043569662","display_name":"Robert M. Sharkey","orcid":"https://orcid.org/0000-0003-1408-0905","observed_orcids":["https://orcid.org/0000-0003-1408-0905"]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]},{"id":"https://openalex.org/I4210131484","display_name":"Center for Molecular Medicine and Immunology","ror":"https://ror.org/03fhjvs31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210131484"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. M. Sharkey","raw_affiliation_strings":["CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ","institution_ids":["https://openalex.org/I4210126919","https://openalex.org/I4210131484"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045775470","display_name":"Habibe Karacay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]},{"id":"https://openalex.org/I4210131484","display_name":"Center for Molecular Medicine and Immunology","ror":"https://ror.org/03fhjvs31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210131484"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Karacay","raw_affiliation_strings":["CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ","institution_ids":["https://openalex.org/I4210126919","https://openalex.org/I4210131484"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081115269","display_name":"Pierre-Yves Brard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]},{"id":"https://openalex.org/I4210131484","display_name":"Center for Molecular Medicine and Immunology","ror":"https://ror.org/03fhjvs31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210131484"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Y. Brard","raw_affiliation_strings":["CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ","institution_ids":["https://openalex.org/I4210126919","https://openalex.org/I4210131484"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109452807","display_name":"C.-H. Chang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]},{"id":"https://openalex.org/I4210131484","display_name":"Center for Molecular Medicine and Immunology","ror":"https://ror.org/03fhjvs31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210131484"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. H. Chang","raw_affiliation_strings":["CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ","institution_ids":["https://openalex.org/I4210126919","https://openalex.org/I4210131484"]}]},{"author_position":"middle","author":{"id":null,"display_name":"W. J. McBride","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]},{"id":"https://openalex.org/I4210131484","display_name":"Center for Molecular Medicine and Immunology","ror":"https://ror.org/03fhjvs31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210131484"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. J. McBride","raw_affiliation_strings":["CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ","institution_ids":["https://openalex.org/I4210126919","https://openalex.org/I4210131484"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062966348","display_name":"Ivan David Horak","orcid":"https://orcid.org/0009-0003-8726-4016","observed_orcids":["https://orcid.org/0009-0003-8726-4016"]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]},{"id":"https://openalex.org/I4210131484","display_name":"Center for Molecular Medicine and Immunology","ror":"https://ror.org/03fhjvs31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210131484"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. D. Horak","raw_affiliation_strings":["CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ","institution_ids":["https://openalex.org/I4210126919","https://openalex.org/I4210131484"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003890903","display_name":"David M. Goldenberg","orcid":"https://orcid.org/0000-0001-5539-421X","observed_orcids":["https://orcid.org/0000-0001-5539-421X"]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]},{"id":"https://openalex.org/I4210131484","display_name":"Center for Molecular Medicine and Immunology","ror":"https://ror.org/03fhjvs31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210131484"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. M. Goldenberg","raw_affiliation_strings":["CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CMMI, Belleville, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ","institution_ids":["https://openalex.org/I4210126919","https://openalex.org/I4210131484"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"2548","last_page":"2548"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/radioimmunotherapy","display_name":"radioimmunotherapy","score":0.9229999780654907},{"id":"https://openalex.org/keywords/pretargeting","display_name":"pretargeting","score":0.9380000233650208},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.9710000157356262},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.7020000219345093},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.8550000190734863},{"id":"https://openalex.org/keywords/yttrium-90","display_name":"yttrium-90","score":0.9020000100135803},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.5199999809265137},{"id":"https://openalex.org/keywords/anti-hapten-antibodies","display_name":"hapten-specific antibodies","score":0.5450000166893005},{"id":"https://openalex.org/keywords/b-cell-lymphoma","display_name":"B-cell lymphoma","score":0.703000009059906},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.7509999871253967},{"id":"https://openalex.org/keywords/tissue-distribution","display_name":"tissue distribution","score":0.8069999814033508},{"id":"https://openalex.org/keywords/therapeutic-window","display_name":"therapeutic window","score":0.6399999856948853},{"id":"https://openalex.org/keywords/refractory-lymphoma","display_name":"refractory lymphoma","score":0.609000027179718},{"id":"https://openalex.org/keywords/nude-mouse-model","display_name":"nude mouse model","score":0.6600000262260437}],"concepts":[{"id":"https://openalex.org/C2777836882","wikidata":"https://www.wikidata.org/wiki/Q22907915","display_name":"Pretargeting","level":5,"score":0.9911888837814331},{"id":"https://openalex.org/C2776146153","wikidata":"https://www.wikidata.org/wiki/Q7281276","display_name":"Radioimmunotherapy","level":4,"score":0.9312428832054138},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7869955897331238},{"id":"https://openalex.org/C2777807558","wikidata":"https://www.wikidata.org/wiki/Q4914764","display_name":"Biodistribution","level":3,"score":0.5280928015708923},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4784843325614929},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.42984139919281006},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4286743402481079},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33333620429039},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.33251017332077026},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2917269170284271},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.22967371344566345},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.1241317093372345},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.08011066913604736},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.2548","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.2548","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.2548","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2044958968","https://openalex.org/W2138994942","https://openalex.org/W2554220029","https://openalex.org/W2564891902","https://openalex.org/W2200499915","https://openalex.org/W7095724811","https://openalex.org/W2030765561","https://openalex.org/W1989246891","https://openalex.org/W2007734777","https://openalex.org/W2006928831"],"abstract_inverted_index":{"2548":[0],"Background:":[1],"Radioimmunotherapy":[2],"(RAIT)":[3],"is":[4],"an":[5],"approved":[6],"treatment":[7,133,305],"of":[8,27,34,56,101,105,118,134,139,151,162,175,184,217,250,258,306],"follicular":[9],"and":[10,156,206,236,274,321],"transformed":[11],"non-Hodgkin\u2019s":[12],"lymphoma":[13,94],"(NHL)":[14],"that":[15,50,69,294],"uses":[16],"anti-CD20":[17,108],"IgGs":[18],"radiolabeled":[19,80,289,312],"with":[20,247],"90Y":[21],"or":[22,136,165,331,334],"131I.":[23],"Administered":[24],"in":[25,53,186,212,225,315],"cases":[26],"refractory":[28],"disease,":[29],"there":[30],"are":[31],"a":[32,63,98,106,119,126,132,295,302],"number":[33],"new":[35],"trials":[36],"assessing":[37],"the":[38,42,54,71,102,116,176,182,187,198,218,226,241,252,259,266,287,322],"prospects":[39],"for":[40,44,74,111,124,197,265],"expanding":[41],"indication":[43],"this":[45],"treatment.":[46,291],"Our":[47],"studies":[48,171,246],"suggest":[49],"significant":[51],"improvements":[52],"therapy":[55],"NHL":[57,307],"could":[58,300],"be":[59,280,301],"obtained":[60],"by":[61],"using":[62],"bispecific":[64],"antibody":[65,123,290],"(bsMAb)":[66],"pretargeting":[67,144,199,230,253,278,298],"procedure":[68,145,200,254,299],"enhances":[70],"therapeutic":[72],"window":[73],"targeted":[75],"radionuclides":[76],"compared":[77,147,261],"to":[78,87,115,148,166,262,271,279],"directly":[79,288,311],"IgG.":[81,243,268],"Methods:":[82],"Nude":[83],"mice":[84],"bearing":[85],"1.0-":[86],"1.5-cm":[88],"diameter":[89],"s.c.":[90],"human":[91],"Ramos":[92],"B-cell":[93],"xenografts":[95],"were":[96],"administered":[97],"bsMAb":[99,297],"composed":[100],"Fab\u2019":[103,117],"fragment":[104],"humanized":[107,296],"MAb":[109],"(hA20)":[110],"tumor":[112,173],"localization":[113],"coupled":[114],"novel":[120],"anti-hapten":[121],"(HSG)":[122],"binding":[125],"90Y-labeled":[127],"HSG-peptide.":[128],"Forty-eight":[129],"hours":[130],"later,":[131],"0.5":[135],"0.8":[137,160,215],"mCi":[138,161,216],"90Y-HSG-peptide":[140,163,219],"was":[141,146,231],"given.":[142],"The":[143],"equitoxic":[149],"amounts":[150],"90Y-hA20":[152,242,267],"IgG":[153,178],"(e.g.,":[154],"0.105":[155],"0.175":[157],"mCi,":[158],"respectively),":[159],"alone,":[164],"untreated":[167,227],"animals.":[168],"Results:":[169],"Biodistribution":[170],"showed":[172,277],"uptake":[174],"90Y-anti-CD20":[177],"did":[179],"not":[180],"exceed":[181],"level":[183],"radioactivity":[185],"blood":[188],"until":[189],"7":[190],"days":[191],"after":[192],"injection,":[193],"whereas":[194],"tumor/blood":[195],"ratios":[196],"where":[201],"3:1":[202],"within":[203,208],"3":[204],"h":[205],"30:1":[207],"24":[209],"h.":[210],"Tumors":[211],"animals":[213,239,260],"given":[214],"alone":[220],"progressed":[221],"as":[222,224],"rapidly":[223],"group,":[228],"while":[229],"more":[232,303],"effective":[233,304],"at":[234],"controlling":[235],"even":[237],"curing":[238],"than":[240,286,308],"In":[244],"several":[245],"6":[248],"months":[249],"observation,":[251],"has":[255],"cured":[256],"\u226550%":[257],"\u2264":[263],"10%":[264],"Conclusions:":[269],"Time":[270],"disease":[272],"progression":[273],"survival":[275],"analyses":[276],"significantly":[281],"better":[282],"(P":[283],"<":[284],"0.005)":[285],"This":[292],"suggests":[293],"currently":[309],"available":[310],"antibodies.":[313],"(Supported":[314],"part":[316],"from":[317],"DOE":[318],"grant":[319],"DE-FG02-95ER62028":[320],"Thomas":[323],"&":[324],"Agnes":[325],"Carvel":[326],"Foundation.)":[327],"Author":[328],"Disclosure":[329],"Employment":[330],"Leadership":[332],"Consultant":[333],"Advisory":[335],"Role":[336],"Stock":[337],"Ownership":[338],"Honoraria":[339],"Research":[340],"Funding":[341],"Expert":[342],"Testimony":[343],"Other":[344],"Remuneration":[345],"IBC":[346],"Pharmaceuticals,":[347],"Immunomedics":[348,349]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2017-03-03T00:00:00"}